The Analysis of Asymetric Dimethylarginine and Homocysteine in Patients with Chronic Kidney Disease

Tetty Hendrawati, Syakib Bakri, Mansyur Arif

Abstract


BACKGROUND: Asymmetric dimethylarginine (ADMA) is a competitive inhibitor of nitric oxide synthase (NOS). ADMA reduces NO synthesis when its concentration elevates. ADMA is a novel risk factor for cardiovascular disease. Plasma ADMA accumulates in patients with endstage renal disease, due to reduced renal clearance. Hyperhomocysteinemia is often found in patients with chronic kidney disease (CKD). Homocysteine may cause ADMA to accumulate; however, the mechanism by which ADMA level elevates in hyperhomocysteinemia is still unclear. Objective of this study was to analyze the concentrations of homocysteine and ADMA and to assess the correlation between homocysteine and ADMA concentrations with the severity of chronic kidney disease.

METHODS: This was a cross-sectional study on 75 patients with CKD, comprising men and women aged 40-70 years. Assessments were done on the concentrations of creatinine, homocysteine, ADMA, fasting blood glucose, cholesterol HDL and triglyceride.

RESULTS: In later stage of CKD there was significantly higher tHcy concentration as compared with the earlier stage of CKD (p=0.0000). In CKD stage 2 to 4 there was a tendency for ADMA concentration to increase to a significant average (p=0.210), but ADMA concentration was lower at stage 5. There was increased ADMA along with increased tHcy concentration of around 20μ mol/L, and this then decreased. The inverse correlation between tHcy and ADMA concentrations started to appear in CKD stage 4, but this correlation was statistically insignificant (r2 =0.19; p=0.499).

CONCLUSIONS: This study showed there was a correlation between homocysteine and ADMA concentrations in patients with CKD stage 2 to 5, although statistically not significant.

KEYWORDS: Asymetric Dimethylarginine, Homocysteine, Chronic Kidney Disease


Full Text:

PDF

References


Bakri S. Deteksi dini dan upaya-upaya pencegahan progresifitas penyakit ginjal kronik. Upacara Penerimaan Jabatan Guru Besar Tetap dalam Bidang Ilmu Penyakit Dalam pada Fakultas Kedokteran. Makassar: Hasanuddin University; 2005.

Levin A, Stevens L, McCullough P. Chronic kidney disease series: cardiovascular disease and the kidney tracking, a killer in chronic kidney disease. PostGraduate Medicine. 2002; 111: 53-60, CrossRef.

Chade AR, Lerman A, Lerman LO. Kidney in early atherosclerosis. Hypertension. 20015; 45: 1042-9, CrossRef.

Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Bio. 2000; 20: 2032-7, CrossRef.

Perna AF, Ingrosso D, Satta E, Romano M, Cimmino A, Galletti P, et al. Metabolic consequences of hyperhomocysteinemia in uremia. Am J Kid Dis. 2001; 38: S85-90, CrossRef.

Vallance P, Leipsi J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylamino hydrolase pathway. Arterioscler Through Vasc Biol. 2004; 24: 1023-30, CrossRef.

Lin KY, Lin SC. A tale of two molecules: nitric oxide and asymmetric dimethylarginine. Acta Cardiol Sin. 2004; 20: 201-11, article.

Dayal S, Lentz SR. ADMA and hyperhocysteinemia. Vasc Med. 2005; 10: S27-33, CrossRef.

Teerlink T. ADMA metabolism and clearance. Vas Med. 2005; 10: S73-81, CrossRef.

Van Guldener C. Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering? Nephrol Dial Transplant. 2006; 21: 1161-6, CrossRef.

Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modelling approach. J Am Soc Neprol. 2005; 16: 2449-45, CrossRef.




DOI: https://doi.org/10.18585/inabj.v1i2.96

Indexed by:

                 

                  

               

     

 

The Prodia Education and Research Institute